Antonio Craxı̀

49.6k total citations · 9 hit papers
519 papers, 27.1k citations indexed

About

Antonio Craxı̀ is a scholar working on Epidemiology, Hepatology and Rheumatology. According to data from OpenAlex, Antonio Craxı̀ has authored 519 papers receiving a total of 27.1k indexed citations (citations by other indexed papers that have themselves been cited), including 394 papers in Epidemiology, 386 papers in Hepatology and 56 papers in Rheumatology. Recurrent topics in Antonio Craxı̀'s work include Liver Disease Diagnosis and Treatment (327 papers), Hepatitis C virus research (295 papers) and Hepatitis B Virus Studies (166 papers). Antonio Craxı̀ is often cited by papers focused on Liver Disease Diagnosis and Treatment (327 papers), Hepatitis C virus research (295 papers) and Hepatitis B Virus Studies (166 papers). Antonio Craxı̀ collaborates with scholars based in Italy, United States and United Kingdom. Antonio Craxı̀'s co-authors include Calogero Cammà, Salvatore Petta, V. Di Marco, Michael Fried, Mitchell L. Shiffman, M. Diago, K. Rajender Reddy, Coleman I. Smith, Dieter Häussinger and Fernando Lopes Gonçales and has published in prestigious journals such as New England Journal of Medicine, The Lancet and JAMA.

In The Last Decade

Antonio Craxı̀

503 papers receiving 26.2k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection

2002 5.1k citations Antonio Craxı̀ et al. profile →
Interferon Alfa-2b Alone or in Combination with Ribavirin for the Treatment of Relapse of Chronic Hepatitis C

1998 1.1k citations Stefan Zeuzem, Antonio Craxı̀ et al. profile →
EASL Clinical Practice Guidelines: Management of hepatitis C virus infection European Association for the Study of the Liver ⇑

2013 797 citations Antonio Craxı̀ et al. profile →
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial

2012 656 citations Antonio Craxı̀, Guido Gerken et al. Journal of Hepatology profile →
Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: Meta-Analysis of Randomized Controlled Trials

2002 650 citations Calogero Cammà, Pietro Andreoné et al. profile →
Preoperative Radiotherapy for Resectable Rectal Cancer

2000 566 citations Calogero Cammà, Antonio Craxı̀ et al. profile →
Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial

2014 333 citations Graham R. Foster, Antonio Craxı̀ et al. The Lancet profile →
Lean NAFLD: A Distinct Entity Shaped by Differential Metabolic Adaptation

2019 240 citations Salvatore Petta, Antonio Craxı̀ et al. profile →
Hepatitis B Virus-Associated Hepatocellular Carcinoma

2022 112 citations Giacomo Emanuele Maria Rizzo, Giuseppe Cabibbo et al. profile →

Peers

Countries citing papers authored by Antonio Craxı̀

Since Specialization

Citations

This map shows the geographic impact of Antonio Craxı̀'s research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Antonio Craxı̀ with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Antonio Craxı̀ more than expected).

Fields of papers citing papers by Antonio Craxı̀

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Antonio Craxı̀. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Antonio Craxı̀. The network helps show where Antonio Craxı̀ may publish in the future.

Co-authorship network of co-authors of Antonio Craxı̀

This figure shows the co-authorship network connecting the top 25 collaborators of Antonio Craxı̀. A scholar is included among the top collaborators of Antonio Craxı̀ based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Antonio Craxı̀. Antonio Craxı̀ is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Effect of pharmacological interventions and placebo on liver Histology in nonalcoholic steatohepatitis: A network meta-analysis 2022 ·Nutrition Metabolism and Cardiovascular Diseases ·Grazia Pennisi, Ciro Celsa, Marco Enea, (unknown), V. Di Marco, (unknown), (unknown), Claudia La Mantia, (unknown), Federica Vernuccio, Antonio Craxı̀, Calogero Cammà, Salvatore Petta	17
2	The impact of direct acting antivirals on hepatitis C virus disease burden and associated costs in four european countries 2021 ·Liver International ·Francesco Saverio Mennini, Andrea Marcellusi, Sarah Robbins Scott, Simona Montilla, Antonio Craxı̀, Marı́a Buti, Liana Gheorghe, Stephen Ryder, Loreta A. Kondili	18
3	Absolute targets for HCV elimination and national health policy paradigms: Foreseeing future requirements 2021 ·Liver International ·Loreta A. Kondili, Antonio Craxı̀, Alessio Aghemo	14
4	Impact of direct acting antivirals (DAAs) on cardiovascular events in HCV cohort with pre-diabetes 2021 ·Nutrition Metabolism and Cardiovascular Diseases ·Ferdinando Carlo Sasso, Pia Clara Pafundi, Alfredo Caturano, Raffaele Galiero, Erica Vetrano, Riccardo Nevola, Salvatore Petta, Anna Ludovica Fracanzani, Carmine Coppola, V. Di Marco, (unknown), Rosa Lombardi, Mauro Giordano, Antonio Craxı̀, Alessandro Perrella, Celestino Sardu, Raffaele Marfella, Teresa Salvatore, Luigi Elio Adinolfi, Luca Rinaldi	44
5	Optimizing diagnostic algorithms to advance Hepatitis C elimination in Italy: A cost effectiveness evaluation 2021 ·Liver International ·Andrea Marcellusi, Francesco Saverio Mennini, Murad Ruf, Claudio Galli, Alessio Aghemo, Maurizia Rossana Brunetto, Sergio Babudieri, Antonio Craxı̀, Massimo Andreoni, Loreta A. Kondili	8
6	Optimizing Sequential Systemic Therapies for Advanced Hepatocellular Carcinoma: A Decision Analysis 2020 ·Cancers ·Giuseppe Cabibbo, Ciro Celsa, Marco Enea, Salvatore Battaglia, Giacomo Emanuele Maria Rizzo, Stefania Grimaudo, Domenica Matranga, Massimo Attanasio, Paolo Bruzzi, Antonio Craxı̀, Calogero Cammà	16
7	SARS-CoV-2 Viral Load, IFNλ Polymorphisms and the Course of COVID-19: An Observational Study 2020 ·Journal of Clinical Medicine ·Emanuele Amodio, Rosaria Maria Pipitone, Stefania Grimaudo, Palmira Immordino, Carmelo Massimo Maida, Tullio Prestileo, Vincenzo Restivo, Fabio Tramuto, Francesco Vitale, Antonio Craxı̀, Alessandra Casuccio	31
8	Optimization of hepatitis C virus screening strategies by birth cohort in Italy 2020 ·Liver International ·Loreta A. Kondili, Ivane Gamkrelidze, Sarah Blach, Andrea Marcellusi, Massimo Galli, Salvatore Petta, Massimo Puoti, Stefano Vella, Homie Razavi, Antonio Craxı̀, Francesco Saverio Mennini, (unknown)	31
9	Progression-Free Survival Early Assessment Is a Robust Surrogate Endpoint of Overall Survival in Immunotherapy Trials of Hepatocellular Carcinoma 2020 ·Cancers ·Giuseppe Cabibbo, Ciro Celsa, Marco Enea, Salvatore Battaglia, Giacomo Emanuele Maria Rizzo, (unknown), Domenica Matranga, Massimo Attanasio, María Reig, Antonio Craxı̀, Calogero Cammà	20
10	Impact of COVID-19 on global HCV elimination efforts 2020 ·Journal of Hepatology ·Sarah Blach, Loreta A. Kondili, Alessio Aghemo, (unknown), Ellen Dugan, Chris Estes, Ivane Gamkrelidze, (unknown), Jean–Michel Pawlotsky, Devin Razavi‐Shearer, Homie Razavi, Imam Waked, Stefan Zeuzem, Antonio Craxı̀	184
11	Aminopyrine breath test predicts liver‐related events and death in HCV‐related cirrhosis on SVR after DAA therapy 2019 ·Liver International ·Salvatore Petta, Francesca Rini, Vincenza Calvaruso, Calogero Cammà, Stefania Ciminnisi, V. Di Marco, Edoardo G. Giannini, Stefania Grimaudo, Rosaria Maria Pipitone, Antonio Craxı̀	1
12	Evaluating the association of serum ferritin and hepatic iron with disease severity in non‐alcoholic fatty liver disease 2019 ·Liver International ·Elena Buzzetti, Salvatore Petta, (unknown), Tu Vinh Luong, Daniela Cabibi, Elena Corradini, Antonio Craxı̀, Massimo Pinzani, Emmanuel Tsochatzis, Antonello Pietrangelo	71
13	Subclinical cardiovascular damage in patients with HCV cirrhosis before and after treatment with direct antiviral agents: a prospective study 2018 ·Alimentary Pharmacology & Therapeutics ·Giuseppina Novo, (unknown), Lydia Giannitrapani, (unknown), (unknown), (unknown), Salvatore Petta, Maurizio Soresi, Giuseppe Montalto, Salvatore Novo, Antonio Craxı̀, Anna Licata	14
14	Management of infections pre- and post-liver transplantation: Report of an AISF consensus conference 2014 ·Journal of Hepatology ·S. Fagiuoli, Agostino Colli, Raffaele Bruno, Antonio Craxı̀, Giovanni Battista Gaeta, Paolo Grossi, Mario U. Mondelli, Massimo Puoti, Evangelista Sagnelli, Stefania Stefani, Pierluigi Toniutto, Patrizia Burra	74
15	Steatosis affects the performance of liver stiffness measurement for fibrosis assessment in patients with genotype 1 chronic hepatitis C 2014 ·Default journal ·Daniela Cabibi, Giuseppe Cabibbo, Calogero Cammà, Antonio Craxı̀, Salvatore Petta, (unknown), V. Di Marco, Marcello Maida, Fabio Salvatore Macaluso	2
16	603 A MULTICENTER ITALIAN CROSS-SECTIONAL STUDY IN ELDERLY PATIENTS WITH HEPATITIS C VIRUS (HCV) INFECTION 2009 ·Journal of Hepatology ·Fabio Conti, Mario Luca Morieri, Annagiulia Gramenzi, Calogero Cammà, Antonio Grieco, A. Picciotto, Gloria Taliani, (unknown), (unknown), (unknown), F. Ancarani, M. Chiaramonte, Gabriella Verucchi, Antonio Craxı̀, Mauro Bernardi, Pietro Andreoné	1
17	Cost-Effectiveness of Combination Peginterferon alpha-2a and Ribavirin Compared With Interferon alpha-2b and Ribavirin in Patients With Chronic Hepatitis C 2004 ·The American Journal of Gastroenterology ·Sean D. Sullivan, Donald M. Jensen, David Bernstein, Tarek Hassanein, Graham R. Foster, Shu‐Kuang Lee, Hugo Cheinquer, Antonio Craxı̀, Graham Cooksley, Winslow Klaskala, Kristen Pettit, Kiran Klaus Patel, (unknown)	47
18	Heterogeneity of HVR-1 quasispecies is predictive of early but not sustained virological response in genotype 1b-infected patients undergoing combined treatment with PEG- or STD-IFN plus RBV. 2004 ·PubMed ·Isabella Abbate, (unknown), Oreste Lo Iacono, Roberta Longo, Donatella Ferraro, G. Antonucci, V. Di Marco, R. Di Stefano, Antonio Craxı̀, Mariacarmela Solmone, Alberto Spanò, Giuseppe Ippolito, Maria Rosaria Capobianchi	5
19	The treatment effect of alpha interferon in chronic hepatitis B is independent of pre-treatment variables. Results based on individual patient data from 10 clinical controlled trials 1994 ·Journal of Hepatology ·Kim Krogsgaard, (unknown), Niels Bindslev, Erik Christensen, Antonio Craxı̀, P. Schlichting, Solko W. Schalm, Vicente Carréño, C. Trépo, Guido Gerken, Howard C. Thomas, Per Kragh Andersen, Helmer Ring‐Larsen	70
20	CLINICAL SIGNIFICANCE OF ANTIBODY TO THE HEPATITIS DELTA VIRUS IN SYMPTOMLESS HBsAg CARRIERS 1985 ·The Lancet ·Sarino Aricò, Mario Rizzetto, Alessandro Zanetti, (unknown), M. Arnone, Antonio Ascione, Giuseppe Pastore, Marcello Aragona, F. Caredda, G. Marinucci, Patrizia Farci, Nicola Caporaso, P Dentico, Giovanni Raimondo, Antonio Craxı̀	52

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact